Page 137 - 《中国药房》2023年5期

参考文献 macokinetics/pharmacodynamics-based optimal dosing
[ 1 ] SADEGHI MOGHADDAM T，NAMAEI M H，AFSHAR for multidrug-resistant tuberculosis[J]. Int J Antimicrob
D，et al. High frequency of SCCmec type Ⅳ and multidrug- Agents，2022，59（6）：106589.
resistant SCCmec type Ⅰ among hospital acquired [15] WANG X P，WANG Y F，YAO F，et al. Pharmacokinetics
methicillin-resistant Staphylococcus aureus isolates in of linezolid dose adjustment for creatinine clearance in
Birjand Imam Reza Hospital，Iran[J]. Iran J Microbiol， critically ill patients：a multicenter，prospective，open-
2022，14（1）：67-75. label，observational study[J]. Drug Des Devel Ther，2021，
[ 2 ] 唐翎，刘春军 . 利奈唑胺临床应用研究概述[J]. 中国药 15：2129-2141.
师，2012，15（9）：1345-1347. [16] RAYNER C R，FORREST A，MEAGHER A K，et al.
[ 3 ] TAYAL A，SINGH N P，RAI S，et al. First study on detec‐ Clinical pharmacodynamics of linezolid in seriously ill pa‐
tion of cryptic resistance to linezolid among clinical iso‐ tients treated in a compassionate use programme[J]. Clin
lates of methicillin resistant Staphylococcus aureus from Pharmacokinet，2003，42（15）：1411-1423.
India[J]. Indian J Med Microbiol，2022，40（3）：384-388. [17] ZHENG X B，DAVIES FORSMAN L，BAO Z W，et al.
[ 4 ] YANG G，YAN Y S，MAO J，et al. Development and vali‐ Drug exposure and susceptibility of second-line drugs cor‐
dation of an HPLC-UV method for quantitation of line‐ relate with treatment response in patients with multidrug-
zolid：application to resistance study using in vitro PK/PD resistant tuberculosis：a multicentre prospective cohort
model[J]. Infect Drug Resist，2021，14：5089-5098. study in China[J]. Eur Respir J，2022，59（3）：2101925.
[ 5 ] MOCKELIUNAS L，KEUTZER L，STURKENBOOM M [18] MAO J，LI T，ZHANG N，et al. Dose optimization of com‐
G G，et al. Model-informed precision dosing of linezolid bined linezolid and fosfomycin against Enterococcus by
in patients with drug-resistant tuberculosis[J]. Pharmaceu‐ using an in vitro pharmacokinetic/pharmacodynamic
tics，2022，14（4）：753. model[J]. Microbiol Spectr，2021，9（3）：e0087121.
[ 6 ] BO S Y，SU A M，YANG F，et al. Risk factors for develop‐ [19] VINH D C，RUBINSTEIN E. Linezolid：a review of safety
ment of hematotoxicity in elderly patients treated with li‐ and tolerability[J]. J Infect，2009，59（Suppl 1）：S59-S74.
nezolid[J]. Zhonghua Jie He He Hu Xi Za Zhi，2022，45 [20] TSUJI Y，HIRAKI Y，MATSUMOTO K，et al. Thrombo‐
（6）：533-538. cytopenia and anemia caused by a persistent high linezolid
[ 7 ] KAWASUJI H，TSUJI Y，OGAMI C，et al. Initially re‐ concentration in patients with renal dysfunction[J]. J In‐
duced linezolid dosing regimen to prevent thrombocytope‐ fect Chemother，2011，17（1）：70-75.
nia in hemodialysis patients[J]. Antibiotics （Basel），2021， [21] DAI Y，JIANG S Y，CHEN X O，et al. Analysis of the risk
10（5）：496. factors of linezolid-related haematological toxicity in
[ 8 ] SAZDANOVIC P，JANKOVIC S M，KOSTIC M，et al. Chinese patients[J]. J Clin Pharm Ther，2021，46（3）：
Pharmacokinetics of linezolid in critically ill patients[J]. 807-813.
Expert Opin Drug Metab Toxicol，2016，12（6）：595-600. [22] CATTANEO D，GERVASONI C，COZZI V，et al. Thera‐
[ 9 ] ONG V，FLANAGAN S，FANG E，et al. Absorption，dis‐ peutic drug management of linezolid：a missed opportu‐
tribution，metabolism，and excretion of the novel antibac‐ nity for clinicians?[J]. Int J Antimicrob Agents，2016，48
terial prodrug tedizolid phosphate[J]. Drug Metab Dispos， （6）：728-731.
2014，42（8）：1275-1284. [23] LIU C，BAYER A，COSGROVE S E，et al. Clinical prac‐
[10] EL-GAML R M，EL-KHODARY N M，ABOZAHRA R R， tice guidelines by the Infectious Diseases Society of
et al. Applying pharmacokinetic/pharmacodynamic mea‐ America for the treatment of methicillin-resistant Staphy‐
surements for linezolid in critically ill patients：optimizing lococcus aureus infections in adults and children：execu‐
efficacy and reducing resistance occurrence[J]. Eur J Clin tive summary[J]. Clin Infect Dis，2011，52（3）：285-292.
Pharmacol，2022，78（8）：1301-1310. [24] DAVID N. GILBERT M D.热病：桑福德抗微生物治疗指
[11] HEIDARI S，KHALILI H. Linezolid pharmacokinetics：a 南[M]. 48 版 . 北京：中国协和医科大学出版社，2019：
systematic review for the best clinical practice[J]. Eur J 96-109.
Clin Pharmacol，2023，79（2）：195-206. [25] ZAHEDI BIALVAEI A，RAHBAR M，YOUSEFI M，et al.
[12] SLATTER J G，STALKER D J，FEENSTRA K L，et al. Linezolid：a promising option in the treatment of gram-
Pharmacokinetics，metabolism，and excretion of linezolid positives[J]. J Antimicrob Chemother，2017，72（2）：354-364.
following an oral dose of [（14）C]linezolid to healthy human [26] WU F，ZHANG X S，DAI Y，et al. Dosage strategy of li‐
subjects[J]. Drug Metab Dispos，2001，29（8）：1136-1145. nezolid according to the trough concentration target and
[13] MEAGHER A K，FORREST A，RAYNER C R，et al. renal function in Chinese critically ill patients[J]. Front
Population pharmacokinetics of linezolid in patients Pharmacol，2022，13：844567.
treated in a compassionate-use program[J]. Antimicrob [27] BANDÍN-VILAR E， GARCÍA-QUINTANILLA L，
Agents Chemother，2003，47（2）：548-553. CASTRO-BALADO A，et al. A review of population phar‐
[14] ZHOU W Q，NIE W J，WANG Q F，et al. Linezolid phar‐ macokinetic analyses of linezolid[J]. Clin Pharmacokinet，

中国药房 2023年第34卷第5期 China Pharmacy 2023 Vol. 34 No. 5 · 639 ·